Effect of N6-methyladenosine on fat-cell glucose metabolism. Evidence for two modes of action.
N6-Methyladenosine strongly stimulates [1-14C]glucose oxidation in rat adipocytes [J.E. Souness and V. Chagoya de Sanchez, Fedn Eur. Biochem. Soc. Lett. 125, 249 (1981)]. The effect of the adenosine analogue is largely independent of its action as an R-site agonist. Removal of endogenous adenosine was a prerequisite for the manifestation of the effect of N6-methyladenosine. Nucleoside uptake inhibitors, dipyridamole and nitrobenzylthioinosine, did not block the action of N6-methyladenosine on [1-14C]glucose oxidation. The effect of the adenosine analogue was not greatly influenced by N6-phenylisopropyladenosine, nicotinic acid or theophylline. Although N6-methyladenosine stimulated 3-O-methylglucose uptake into fat cells, it is uncertain whether this was its only effect on glucose metabolism, in view of the comparable enhancement of hexose transport elicited by N6-phenylisopropyladenosine, a much weaker stimulator of glucose oxidation. That hexose transport is not the sole site of action of N6-methyladenosine was supported by the finding that, under conditions which have been proposed to make glucose transport rate limiting, the adenosine analogue only weakly enhanced [1-14C]glucose oxidation. The conversion of glucose carbon 1 to 14CO2 was enhanced by N6-methyladenosine to a greater degree than that of carbon 6, suggesting an increase in pentose phosphate shunt activity. Mechanisms by which this could arise are discussed. Although similarities exist between the effects of insulin and N6-methyladenosine on adipocyte glucose metabolism, the mechanisms by which they stimulate glucose oxidation appear to be distinct, in view of the additivity of their actions on [1-14C]glucose conversion to 14CO2. The results indicate that N6-methyladenosine affects fat-cell glucose metabolism via two different mechanisms: (1) a weak R-site-dependent mode of action related to stimulation of glucose transport and inhibition of lipolysis, and (2) a strong R-site-independent effect of unknown mechanism.
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D003070:Coformycin / Q000031:analogs & derivatives / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D005990:Glycerol / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D009705:Nucleosides / Q000378:metabolism; D010084:Oxidation-Reduction; D015649:Pentostatin; D051381:Rats; D011919:Rats, Inbred Strains; D013806:Theophylline / Q000494:pharmacology
D005227:Fatty Acids; D009705:Nucleosides; D003070:Coformycin; D015649:Pentostatin; D013806:Theophylline; C010223:N-methyladenosine; D000242:Cyclic AMP; D005947:Glucose; D000241:Adenosine; D005990:Glycerol